What Progress In The Rare Disease, Osteogenesis Imperfecta?

Osteogenesis imperfecta, or brittle bone disease, is a rare condition that is more familiar than most to the general public, as it can have a debilitating effect on younger children and be distressing to parents, patients and family members. But the condition has few if any effective therapies on the market or in development, a fact that backs the acceptance of Mereo BioPharma Group Ltd.’s investigational osteogenesis imperfecta product BPS-804 into the European Medicines Agency’s adaptive pathways program, announced Feb. 20.

BPS-804 is a monoclonal antibody that stimulates the formation of bone by osteoblasts through inhibiting sclerostin, a protein that in...